Dr. Loebel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
18 Beach Ave
Larchmont, NY 10538- Is this information wrong?
Education & Training
- Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalResidency, Psychiatry, 1986 - 1990
- University of Washington School of MedicineClass of 1986
Certifications & Licensure
- NY State Medical License 1989 - 2025
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis.Joseph F Goldberg, Cynthia Siu, Michael Tocco, Andrei Pikalov, Antony Loebel> ;The Journal of Clinical Psychiatry. 2023 Jun 7
- 33 citationsSafety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.Christoph U Correll, Kenneth S Koblan, Seth C Hopkins, Yan Li, Heather Dworak, Robert Goldman, Antony Loebel> ;NPJ Schizophrenia. 2021 Dec 9
- 6 citationsA Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bi...Antony Loebel, Kenneth S. Koblan, Joyce Tsai, Ling Deng, Maurizio Fava, Justine Kent, Seth C. Hopkins> ;Journal of Affective Disorders. 2022 Jan 1
- Join now to see all
Authored Content
- Clinical Relevance Versus Statistical Significance: DelBello and Colleagues Respond to EditorialApril 2018
- Efficacy and Safety of Lurasidone in Children and Adolescents with Bipolar I Depression: A Double-Blind, Placebo-Controlled StudyOctober 2017
- Efficacy and Safety of Lurasidone in Children and Adolescents with Bipolar I Depression: A Double-Blind, Placebo-Controlled StudyOctober 2017
Press Mentions
- Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization CollaborationSeptember 30th, 2021
- Sunovion Pens $890M Otsuka Pact for a Clutch of Neuropsychiatric DrugsSeptember 30th, 2021
- NeuroPace Launches Epilepsy Platform to Personalize Seizure CareAugust 4th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: